NCT01248117View on ClinicalTrials.gov

Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

DRUG

ranibizumab 2.0mg

Monthly, intravitreal injection 0.05ml

Trial Locations (2)

96701

RECRUITING

Retina Consultants of Hawaii, ‘Aiea

96819

RECRUITING

Retina Consultants of Hawaii, Inc, Honolulu

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Retina Consultants of Hawaii

OTHER